Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 113

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 113
---
 can improve the biodistribution and accumulation of the proteins at the desired sites of action,
such as inflamed tissues, or infected cells, thus increasing their efficacy and reducing their side effects.

<div align='center'>72</div>

LPLT protein delivery technology is patent protected.

Pursuant to the Yissum License Agreements,
we have an exclusive, worldwide license for the development, use, manufacture and commercialization of products arising out of patents
owned by, and patent applications filed by, Yissum in connection with LPLT vaccination approach.

The patent listed below was licensed to us
on an exclusive basis by Yissum pursuant to the Yissum License Agreements.

| Status  |     | Country |     | Application 
 Date        |     | Publication  
 Number       |     | Patent   
 Date     |     |    Patent 
    Number |     | Expiry   
 Date     |
| Granted |     | US      |     | May         
 5, 2006     |     | 2006/0252717 |     | March    
 18, 2014 |     | 8,673,285 |     | February 
 18, 2027 |

The U.S. patent referenced above relate to
the proprietary lipid-based delivery system developed in Prof. Barenholz’s laboratory at the Hebrew University of Jerusalem. This
patent, protects the composition and method of use of a liposomal nanoparticle platform incorporating ceramide carbamoyl spermine (CCS)
for the delivery of recombinant protein antigens in vaccine formulations. They include composition of matter claims and methods of use
for prophylactic and therapeutic immunization.

Planned Patent Applications and Timeline

Our liposomal vaccine platform is designed
to co-encapsulate multiple recombinant protein antigens within a proprietary lipid nanoparticle system incorporating ceramide carbamoyl
spermine (CCS), a synthetic lipid developed to enhance immunogenicity, antigen stability, and mucosal delivery. As mentioned previously,
this platform has been initially evaluated in preclinical models for two viral targets: SARS-CoV-2 and West Nile Virus (WNV). The dual-antigen
design includes the receptor binding domain (RBD) and nucleocapsid (N) proteins for SARS-CoV-2, and the EDIII and NS1 proteins for WNV,
offering both neutralizing antibody and T-cell mediated immune responses.

Assuming the acceptable outcome of the ongoing